TNT 009

Drug Profile

TNT 009

Alternative Names: TNT-009

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator True North Therapeutics
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune haemolytic anaemia; Bullous pemphigoid; Renal transplant rejection

Most Recent Events

  • 10 Jan 2017 True North Therapeutics plans additional clinical trials in Cold agglutinin disease in USA and Europe
  • 03 Dec 2016 Pharmacodynamics data from a phase Ib trial in Cold agglutinin disease presented at the 58th Annual Meeting of American Haematology Society (ASH-2016)
  • 03 Dec 2016 Safety and efficacy data from a phase Ib trial in Cold agglutinin disease presented at the 58th Annual Meeting of American Haematology Society (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top